CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.

In conclusion, all these results showed that oroxylin A improved the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-κB pathway, and probably served as a most promising agent for CML treatment. PMID: 24858801 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24858801?dopt=Abstract

Source: Biochemical Pharmacology - May 22, 2014 Category: Drugs & Pharmacology Authors: Wang Y, Miao H, Li W, Yao J, Sun Y, Li Z, Zhao L, Guo Q Tags: Biochem Pharmacol Source Type: research